Eli Lilly, GLP-1
Digest more
Eli Lilly and Company beats earnings, boosts 2026 guidance on GLP-1 drugs Mounjaro/Zepbound. Click here to read my most ...
Eli Lilly just posted one of the most impressive quarters in pharmaceutical history, but the drug powering those numbers may ...
Sales of Zepbound and Mounjaro soared during the second quarter, easily beating Wall Street estimates and widening the gap ...
Eli Lilly (LLY) stock jumps as the firm posts better-than-expected Q2 2026 results, driven by its injectable GLP-1s and its ...
Demand for the healthcare leader's weight-loss drugs continues to rise.
David Ricks, Eli Lilly chairman and CEO, joins 'Squawk Box' to discuss second-quarter earnings and revenue that easily beat ...
Eli Lilly shares rally on a fresh DTC partnership with CVS Health. A strong Q2 release and impressive future guidance is ...
The healthcare stock is up over 300% in five years and has a market cap of around $1 trillion.
Second-quarter revenue jumped 48 percent to $23 billion as demand for Zepbound and Mounjaro pushed Lilly to lift its ...
Sales of Eli Lilly's Zepbound and Mounjaro injectable weight-loss and diabetes drugs soared during the second quarter, easily beating Wall Street ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results